Search

T cells are required for the development of hypertension in male and postmenopausal female mice while premenopausal females are protected from T cell mediated hypertension. To better understand sex differences in immune-cell mediated hypertensive responses, we sought to determine if there were any significant differences in the immune cell profiles of premenopausal female (F), VCD-treated postmenopausal female (PMF), and male (M) mice. Spleens were collected from all mice and processed for flow cytometric analysis of T cell populations (n=8/group). Analysis of splenic T cell populations revealed no significant difference in the frequency of CD3+ or CD4+ T cells between groups (CD3+: F 33.4%, PMF 30.3%, M 30.2% of total lymphocytes, CD4+: F 64.8%, PMF 70.7%, M 67.5% of CD3+ cells). However, postmenopausal females had a significantly lower frequency of splenic CD8+ T cells compared to both males and premenopausal females (CD8+: F 27.9%, PMF 19.5%*, M 25.3% of CD3+ cells *p

Menopause, the cessation of menstrual cycling, is associated with an increase in risk for cardiovascular diseases, including hypertension. Currently, the average age of menopause is 51 and studies have found that the risk factors for postmenopausal diseases begin to develop during perimenopause, the 5- to 10-year period preceding the onset of menopause. Clinical studies have demonstrated that only 36% of postmenopausal women with hypertension have their blood pressure under control, despite taking antihypertensives. Women taking a monotherapy of a beta-blocker, an Angiotensin-converting enzyme (ACE) inhibitor, or a calcium channel blocker are less likely to have their blood pressure under control than women who take a diuretic alone. Discrepancies in disease pathology between pre- and postmenopausal women, and the cause of the reduced effectiveness of the major antihypertensive therapeutics remain unclear. This chapter highlights recent developments in our understanding of postmenopausal hypertension, including potential mechanistic pathways that may provide new treatment paradigms, including the activation of immune cells and inflammatory pathways in the postmenopausal kidney and vasculature.

Coronary heart disease is a leading cause of death among Americans for which coronary artery bypass graft (CABG) surgery is a standard surgical treatment. The success of CABG surgery is impaired by a compliance mismatch between vascular grafts and native vessels. Tissue engineered vascular grafts (TEVGs) have the potential to be compliance matched and thereby reduce the risk of graft failure. Glutaraldehyde (GLUT) vapor-crosslinked gelatin/fibrinogen constructs were fabricated and mechanically tested in a previous study by our research group at 2, 8, and 24 hrs of GLUT vapor exposure. The current study details a computational method that was developed to predict the material properties of our constructs for crosslinking times between 2 and 24 hrs by interpolating the 2, 8, and 24 hrs crosslinking time data. matlab and abaqus were used to determine the optimal combination of fabrication parameters to produce a compliance matched construct. The validity of the method was tested by creating a 16-hr crosslinked construct of 130 μm thickness and comparing its compliance to that predicted by the optimization algorithm. The predicted compliance of the 16-hr construct was 0.00059 mm Hg−1 while the experimentally determined compliance was 0.00065 mm Hg−1, a relative difference of 9.2%. Prior data in our laboratory has shown the compliance of the left anterior descending porcine coronary (LADC) artery to be 0.00071 ± 0.0003 mm Hg−1. Our optimization algorithm predicts that a 258-μm-thick construct that is GLUT vapor crosslinked for 8.1 hrs would match LADC compliance. This result is consistent with our previous work demonstrating that an 8-hr GLUT vapor crosslinked construct produces a compliance that is not significantly different from a porcine coronary LADC.